Mature results from a Swedish comparison study of conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN trial

Radiotherapy and Oncology

Volumn 117, Issue 1, 2015, Pages 99-105

  Zackrisson, Björn ^a   Kjellén, Elisabeth ^b   Söderström, Karin ^a   Brun, Eva ^b   Nyman, Jan ^c   Friesland, Signe ^d   Reizenstein, Johan ^e   Sjödin, Helena ^d   Ekberg, Lars ^b   Lödén, Britta ^f   Franzén, Lars ^a   Ask, Anders ^b   Wickart Johansson, Gun ^d   Lewin, Freddi ^g   Björk Eriksson, Thomas ^c   Lundin, Erik ^e   Dalianis, Tina ^h   Wennerberg, Johan ^b   Johansson, Karl Axel ^c   Nilsson, Per ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f CENTRAL HOSPITAL   (Sweden)

^g RYHOV COUNTY HOSPITAL   (Sweden)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Accelerated fractionation; HNSCC; HPV; p16; Radiotherapy

Indexed keywords

PROTEIN P16;

ACCELERATED RADIOTHERAPY; ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER TISSUE; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LARYNX CARCINOMA; LOCAL RECURRENCE FREE SURVIVAL; MALE; MOUTH CARCINOMA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SWEDEN; WART VIRUS; AGED; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; COMPLICATION; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS TYPE 16; ISOLATION AND PURIFICATION; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROGNOSIS; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84945546848     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2015.09.024     Document Type: Article

References (28)

1. B. Zackrisson, P. Nilsson, E. Kjellén, and et al. Two-year results from a Swedish study on conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - the ARTSCAN study Radiother Oncol 100 2011 41 48
2. S.M. Jackson, L.M. Weir, J.H. Hay, V.H. Tsang, and J.S. Durham A randomized trial of accelerated versus conventional radiotherapy in head and neck cancer Radiother Oncol 43 1997 39 46
3. J.C. Horiot, P. Bontemps, W. Van Den Bogaert, and et al. Accelerated fractionation compared to conventional fractionation improves locoregional control in the radiotherapy of advanced head and neck cancer: results of the EORTC 22851 randomized trial Radiother Oncol 44 1997 39 46
4. K.K. Fu, T.F. Pajak, A. Trotti, and et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 Int J Radiat Oncol Biol Phys 48 2000 7 16
5. K. Skladowski, B. Maciejewski, M. Golen, B. Pilecki, W. Przeorek, and R. Tarnawski Randomized clinical trial on 7-days-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumor control and normal tissue toxicity Radiother Oncol 55 2000 101 110
6. M.G. Poulsen, J.W. Denham, L.J. Peters, and et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a trans-tasman radiation oncology group study Radiother Oncol 60 2001 113 122
7. A. Hliniak, B. Gwiazdowska, Z. Szutkowski, and et al. A multicenter randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time Radiother Oncol 62 2002 1 10
8. J. Overgaard, H.S. Hansen, L. Specht, and et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial Lancet 362 2003 933 940
9. P. Olmi, S. Crispino, C. Fallai, and et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy - a multicenter randomized trial Int J Radiat Oncol Biol Phys 55 2003 78 92
10. J. Bourhis, M. Lapeyre, J. Tortochaux, and et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial J Clin Oncol 24 2006 2873 2878
11. J. Overgaard, B.K. Mohanti, N. Begum, and et al. Five versus six fractions of radiotherapy per week for squamous cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial Lancet Oncol 11 2010 553 560
12. J.J. Beitler, Q. Zhang, K.K. Fu, and et al. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer Int J Radiat Oncol Biol Phys 89 2014 13 20
13. J. Bourhis, J. Overgaard, H. Audry, and et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis Lancet 368 2006 843 854
14. B. Baujat, J. Bourhis, P. Blanchard, and et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer Cochrane Database Syst Rev 12 2010
15. K.K. Ang, J. Harris, R. Wheeler, and et al. Human papillomavirus and survival of patients with oropharyngeal cancer N Engl J Med 363 2010 24 35
16. P. Lassen, H. Primdahl, J. Johansen, and et al. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer Radiother Oncol 113 2014 310 316
17. K.A. Johansson, P. Nilsson, B. Zackrisson, and et al. The quality assurance process for the ARTSCAN head and neck study - a practical interactive approach for QA in 3DCRT and IMRT Radiother Oncol 87 2008 290 299
18. International Commission on Radiation Units and Measurements, I. Prescribing, recording and reporting photon beam therapy report 50. Bethesda, MD; 1993.
19. International Commission on Radiation Units and Measurements, I, (Supplement to ICRU Report 50). Prescribing, recording, and reporting photon beam therapy. Bethesda, MD; 1999.
20. S. Ottosson, B. Zackrisson, E. Kjellén, P. Nilsson, and G. Laurell Weight loss in patients with head and neck cancer during and after conventional and accelerated radiotherapy Acta Oncol 52 2013 711 718
21. U. Lindblom, O. Gärskog, E. Kjellén, and et al. Radiation-induced trismus in the ARTSCAN head and neck trial Acta Oncol 53 2014 620 627
22. J. Bourhis, C. Sire, P. Graff, and et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial Lancet Oncol 13 2012 145 153
23. P. Lassen The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome Radiother Oncol 95 2010 371 380
24. A. Näsman, C. Nordfors, S. Holzhauser, and et al. Incidence of human papillomavirus positive tonsillar and base of tongue carcinoma: a stabilisation of an epidemic of viral induced carcinoma? Eur J Cancer 51 2015 55 61
25. A. Antonsson, R.E. Neale, S. Boros, and et al. Human papillomavirus status and p16(INK4A) expression in patients with mucosal squamous cell carcinoma of the head and neck in Queensland, Australia Cancer Epidemiol 39 2015 174 181
26. C.H. Chung, Q. Zhang, C.S. Kong, and et al. P16 protein expression and human papillomavirus status as prognostic biomarkers of non oropharyngeal head and neck squamous cell carcinoma J Clin Oncol 32 2014 3930 3938
27. J. Thomas, and T. Primeaux Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma? Ann Diagn Pathol 16 2012 91 99
28. P. Lassen, J. Eriksen, A. Krogdahl, and et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial Radiother Oncol 100 2011 49 55